S.Amdt. 1256

SA 1256. Mr. LANKFORD submitted an amendment intended to be proposed
to amendment SA 1092 proposed by Mrs. Murray (for herself and Ms.
Collins) to the bill H.R. 4366, making appropriations for military
construction, the Department of Veterans Affairs, and related agencies
for the fiscal year ending September 30, 2024, and for other purposes;
which was ordered to lie on the table; as follows:

At the appropriate place in title VII of division B, insert
the following:
Sec. 7__. (a) The modifications approved by the Food and
Drug Administration on January 3, 2023, to the risk
evaluation and mitigation strategy under section 505-1 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for
mifepristone shall have no force or effect.
(b) None of the funds made available by this Act may be
used to--
(1) establish, implement, or enforce any provision of a
risk evaluation and mitigation strategy under section 505-1
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1)
for mifepristone that is substantially similar to any of the
modifications nullified by subsection (a); or
(2) exercise discretion to not enforce any provision of a
risk evaluation and mitigation strategy under such section
505-1 for mifepristone.
______